Rajiv Patni is a 25-year veteran of the pharma and public biotech ecosystem. Most recently, he served as Chief R&D Officer at Reata Pharmaceuticals until its acquisition by Biogen in 2023. Previously, he served as Chief Medical Officer at several clinical and commercial-stage companies, including Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals. He joined these companies at inflection points in their R&D trajectory. Earlier in his career, Rajiv held roles at Pfizer, Roche, and Actelion. Rajiv has supported team efforts for initial drug approvals, indication expansions, and acquisitions by larger companies. Notably, these eleven medicines are used for the treatment of common and rare diseases, such as hypertension, heart failure, pulmonary arterial hypertension, direct oral coagulant induced hemorrhagic stroke, advanced Parkinson’s disease, sickle cell disease, and Friedreich’s ataxia. Rajiv received his M.D. from the Icahn School of Medicine at Mount Sinai through an accelerated B.S./M.D. program. He completed an internal medicine residency and an adult cardiology fellowship at the Albert Einstein College of Medicine, where he remained as an attending physician-scientist before joining industry.